Neurocrine Biosciences, Inc. - Common Stock (NBIX)
124.61
+0.09 (0.07%)
NASDAQ · Last Trade: Jun 5th, 8:56 PM EDT
Detailed Quote
Previous Close
124.52
Open
124.03
Bid
105.66
Ask
126.80
Day's Range
123.33 - 125.24
52 Week Range
84.23 - 157.98
Volume
743,323
Market Cap
12.34B
PE Ratio (TTM)
42.24
EPS (TTM)
3.0
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,562,476
Chart
About Neurocrine Biosciences, Inc. - Common Stock (NBIX)
Neurocrine Biosciences is a biopharmaceutical company focused on developing innovative treatments for neurological and endocrine diseases. The company conducts research and creates drug therapies aimed at addressing the unmet medical needs of patients suffering from conditions such as movement disorders, psychiatric disorders, and hormonal disorders. Through a combination of scientific expertise and cutting-edge technology, Neurocrine strives to enhance patient outcomes and improve quality of life, while expanding its pipeline of therapeutic options in the field of neuroscience and endocrinology. Read More
SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Matthew Abernethy, M.B.A., to its Board of Directors effective as of May 29, 2025. Mr. Abernethy brings to the Company over 15 years’ experience in corporate finance and investor relations in the biotech and medical device industry. In addition, the Company announced that Timothy P. Coughlin stepped down from the Board of Directors, effective concurrently with Mr. Abernethy’s appointment.
NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it a candidate for investors seeking affordable growth stocks in the biotech sector.
NEUROCRINE BIOSCIENCES (NBIX) shows strong growth fundamentals and a promising technical setup, making it a stock to watch for potential breakout opportunities.
CEO Kyle Gano highlighted record new patient starts for Ingrezza and noted positive early response to the launch of Crenessity, positioning the company for sustained growth.
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Discover NEUROCRINE BIOSCIENCES INC, an undervalued growth gem. NASDAQ:NBIX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing valuation.
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences.
Discover NEUROCRINE BIOSCIENCES INC, an undervalued stock. NASDAQ:NBIX showcases solid financial health and profitability while maintaining an appealing valuation.
Based on a technical and fundamental analysis of NASDAQ:NBIX we can say: NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
NASDAQ:NBIX is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.
